Kalohexis files confidential IPO draft registration with SEC

Kalohexis, Inc., a clinical-stage biotechnology company focused on the melanocortin system for metabolic diseases including obesity and cancer cachexia, has submitted a confidential draft registration statement on Form S-1 to the Securities and Exchange Commission in connection with a proposed initial public offering of its common stock.

The company has not yet determined the number of shares to be offered or the price range for the proposed offering. The IPO is expected to proceed after the SEC completes its review, subject to market and other conditions.

You May Also Be Interested In

• Aspen Neuroscience prices IPO at $15 per share on Nasdaq
• Kayne Anderson closes $15M preferred share private placement
• SVRN faces Nasdaq delisting after missing annual report deadline